ASCO: Pfizer's Ibrance fails to extend lives in newly diagnosed breast cancer. Will...

cafead

Administrator
Staff member
  • cafead   Jun 06, 2022 at 12:02: AM
via The verdict is in: Pfizer’s Ibrance didn’t improve the life span of patients with newly diagnosed HR-positive, HER2-negative breast cancer in a first-of-its-kind clinical trial.

article source